NEO-Nal- IRI, NCT03483038: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 45 | US | Liposomal Irinotecan, ONIVYDE, FOLFOX regimen | University of Florida, Ipsen | Pancreatic Adenocarcinoma | 09/23 | 12/24 | | |
